Equillium Results Presentation Deck
Safety Data Summary: Type A Cohorts 1-5
Itolizumab was generally well tolerated across all subjects and dose groups (n=35)
Safety Overview
Safety monitored by independent Data Review Committee
49% of subjects experienced at least one adverse event
Mostly in the highest dose cohort where multiple injections were required per dose (89% of subjects in 3.2 mg/kg group)
Most common terms headache and injection site reaction (erythema/pruritus), predominantly in the 3.2 mg/kg group
No deaths
•
•
• 2 SAEs in 1 subject (3.2 mg/kg) unrelated to study treatment, > 30 days after last dose
1 dose limiting toxicity: Grade 3 lymphopenia (2.4 mg/kg)
Based on this safety profile, in conjunction with PK/PD data, 1.6 mg/kg selected for Type B subjects to
be dosed bi-weekly for 24 weeks
equillium
Interim data from 19 AUG 2021: final completion of Type A cohort Abbreviations: PD, Pharmacodynamic: PK, Pharmacodynamic SAE, Serious adverse event
Putterman et al., PO1623 ASN, 2021
16View entire presentation